Skip to main content

Table 1 Characteristics of patients included in this meta-analysis

From: The impact of STAT3 and phospho-STAT3 expression on the prognosis and clinicopathology of ovarian cancer: a systematic review and meta-analysis

Study Country N pts Age (years) p-STAT3+ (%) STAT3+ (%) Pathological type
(cancer/
borderline/
benign/
normal)
Histological type
(S/C/E/M)
FIGO stage
(I-II/III-IV)
Tumour grade (G1 + G2/
G3)
LN
(yes/no)
Anti-
body
Scoring method Cut-off value Follow-up (months) Survival analysis HR estimate NOS score
Yoshikawa (2018) [20] Japan 341 16–82 (53 median) 95 (28%) NR NR S144, M60, E52, C85 166/175 NR NR RmAb NR > 10% median 58 (1–257) OS/PFS HR 8
Yang [21] (2013) USA 49 41–87 (61 median) 25 (51.02%) NR NR SME47, CU2 16/33 18/31 NR Ab E ≥50% NR OS HR 7
Min [22] (2009) China 50 22–73 (50.6 median) 29 (58%) 44 (88%) 50/NR/20/20 S45, M2, C2, O1 18/32 34/16 9/22 Ab I,E(P) 1+, ≥10%(P) NR OS K-M 7
Shang [23] (2017) China 136 21–83 (54 median) 72 (52.94%) 86 (63.23%) NR S72, M36, E15, C13 56/80 52/84 59/77 R Ab EI ≥4 48 OS HR 8
Rosen [24] (2006) USA 303 20–86 (58.2 median) 261 (86%) NR NR S232, M6, E33, C15, O36 56/247 14/289 NR Ab EI ≥3 median 64 (1–120) OS K-M 8
Xiao [25] (2015) China 40 NR 32 (80%) NR 40/20/20/NR NR NR 12/28 31/9 Ab EI ≥3 NR NR NR 5
Gao [26] (2013) China 34 30–78 (55.6 median) NR 28 (82.4%) 34/10/10/NR S18, M10, E4, C2 12/22 19/15 20/14 RmAb E ≥6% NR NR NR 5
Wu [27] (2021) China 130 23–67 (53 median) NR 90 (69.2%) 130/30/20/NR NR 47/83 NR 52/78 MAb EI > 1+ ≥25% NR NR NR 8
Zhang [28] (2008) China 56 34–71 (52.5 median) NR 49 (87.5%) 56/18/35/25 NR 12/44 35/21 32/24 RpAb EI ≥2 NR NR NR 6
Chen [29] (2017) China 31 NR 10 (32.26%) NR NR S15, M4, E7, C5 10/21 NR NR Ab EI ≥3 NR NR NR 8
Li [30] (2020) China 156 23–73 (50.6 median) 86 (55.13%) NR NR S116, M22, E12, O6 46/110 64/84 43/113 Ab E ≥50% median 84 (60–108) OS/PFS K-M 7
Yanaihara [31] (2016) Japan 84 NR 33 (39.29%) NR NR NR 63/21 NR NR Ab EI > 2 NR OS/PFS HR 8
Wouters [32] (2015) Netherland 101 57.99 median 20 (20%) NR NR S57, M7, E18 27/74 NR NR RmAb EI ≥3 NR NR NR 8
Chaluvally_Raghavan [33] (2016) USA 145 35–88 (58.8 median) NR 67 (46.2%) NR S145 9/136 NR/145 NR Ab EI > 1 NR OS K-M 7
Guan [34] (2010) China 42 37–72 (52 median) NR 34 (80.95%) 42/NR/25/13 S29, M9, E4 9/33 NR NR RAb EI ≥3 NR NR NR 6
Hong [35] (2017) China 49 42–76 (63.4 median) NR 34 (69.4%) 49/NR/14/NR NR 35/14 NR NR Ab EI ≥3 NR NR NR 5
  1. N pts number of patients, STAT3 signal transducer and activator of transcription 3, p-STAT3 phospho-STAT3, NR not reported, C clear cell, S serous, E endometrioid, M mucinous, U Undifferentiated, O Others, FIGO International Federation of Gynecology and Obstetrics, LN Lymph node metastasis, M mouse, R rabbit, pAb polyclonal antibody, mAb monoclonal antibody, E extent, I intensity, p phospho-STAT3, OS overall survival, PFS progression-free survival, K-M Kaplan–Meier survival curves, HR hazard ratio, NOS Newcastle–Ottawa Quality Assessment Scale